z-logo
Premium
Mitozantrone‐induced onycholysis. A series of five cases
Author(s) -
CREAMER J.D.,
MORTIMER P.S.,
POWLES T.J.
Publication year - 1995
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/j.1365-2230.1995.tb01377.x
Subject(s) - onycholysis , dermatology , series (stratigraphy) , medicine , paronychia , biology , paleontology
Summary The anthracenedione cytotoxic agent, mitozantrone, has a well‐established place in the treatment of acute leukaemia, lymphoma, breast carcinoma and other malignant tumours. In general it is well tolerated apart from myelosuppression and dose‐related cardiotoxicity. Alopecia is a common side‐effect with mitozantrone but otherwise the skin and its appendages are rarely affected. We present five cases of mitozantrone‐induced onycholysis.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here